The United States Pharmacopeia (USP) has issued a notice announcing revisions to the chemical information for several drug standards. These updates, highlighted in yellow within the respective USP monographs and marked with '(CN 1-Oct-2026)', will officially take effect on October 1, 2026. The revisions impact monographs for Candesartan Cilexetil and Hydrochlorothiazide Tablets, Dronabinol, Insulin Lispro, Nitrofurazone, Octinoxate, Paclitaxel Injection, Trandolapril and Verapamil Hydrochloride Extended-Release Tablets, Triamterene Capsules, and various Verapamil Hydrochloride formulations.

Manufacturers and quality control departments relying on these USP standards must review the updated monographs by the effective date of October 1, 2026. Compliance with these revised chemical standards is necessary to ensure product quality and regulatory adherence. While these are updates to compendial standards and not new regulations, adherence is critical for products marketed in the US that claim USP compliance.